Anthrax News and Research

RSS
Anthrax is an acute infectious disease caused by the spore-forming bacterium Bacillus anthracis. Anthrax most commonly occurs in wild and domestic lower vertebrates (cattle, sheep, goats, camels, antelopes, and other herbivores), but it can also occur in humans when they are exposed to infected animals or tissue from infected animals.

Anthrax is most common in agricultural regions where it occurs in animals. These include South and Central America, Southern and Eastern Europe, Asia, Africa, the Caribbean, and the Middle East. When anthrax affects humans, it is usually due to an occupational exposure to infected animals or their products. Workers who are exposed to dead animals and animal products from other countries where anthrax is more common may become infected with B. anthracis (industrial anthrax). Anthrax outbreaks occur in the United States on an annual basis in livestock and wild game animals such as deer.

Anthrax infection can occur in three forms: cutaneous (skin), inhalation, and gastrointestinal. B. anthracis spores can live in the soil for many years, and humans can become infected with anthrax by handling products from infected animals or by inhaling anthrax spores from contaminated animal products. Anthrax can also be spread by eating undercooked meat from infected animals. It is rare to find infected animals in the United States.
HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

HHS' BARDA contract advances development of novel anthrax vaccine, antitoxin

PharmAthene completes 1,500 liter engineering production run for SparVax anthrax vaccine

PharmAthene completes 1,500 liter engineering production run for SparVax anthrax vaccine

Elusys receives federal contract to develop prophylactic treatment against anthrax

Elusys receives federal contract to develop prophylactic treatment against anthrax

Roche Diagnostics terminates sales and distribution agreement with Response

Roche Diagnostics terminates sales and distribution agreement with Response

Study may help explain plague's rapid evolution and aid in development of therapeutics

Study may help explain plague's rapid evolution and aid in development of therapeutics

Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial

Emergent announces results of adjuvanted BioThrax anthrax vaccine Phase 1a trial

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

PLoS One publishes data from recent animal studies of NanoBio's intranasal RSV vaccine

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

Researchers discover NPC1 protein as crucial for Ebola virus to enter host cells

DTU, TGen researchers pinpoint source of cholera outbreak in Haiti

DTU, TGen researchers pinpoint source of cholera outbreak in Haiti

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

NIH, NanoBio sign licensing agreement to develop vaccine against RSV infections

Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results

Clinical Vaccine Immunology publishes NanoBio's NB-1008 influenza study results

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

PharmAthene demonstrates 36 month stability of rPA anthrax vaccine program candidate

Researchers identify new component of plague causing bacterium that can be used as a vaccine

Researchers identify new component of plague causing bacterium that can be used as a vaccine

Copenhagen chemist reveals mechanism behind deadly infections

Copenhagen chemist reveals mechanism behind deadly infections

U.S. FDA approves generic Levaquin for treatment of bacterial infections

U.S. FDA approves generic Levaquin for treatment of bacterial infections

Scientists uncover how immune system responds to invading anthrax bacteria

Scientists uncover how immune system responds to invading anthrax bacteria

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Aradigm demonstrates top line data from ORBIT-1 ARD-3100 Phase 2b study for bronchiectasis

Response Biomedical NTproBNP Assay does not meet FDA regulatory criteria for CLIA waiver

Response Biomedical NTproBNP Assay does not meet FDA regulatory criteria for CLIA waiver

PharmAthene to sell $6.5M of common stock and warrants in registered direct offering

PharmAthene to sell $6.5M of common stock and warrants in registered direct offering

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

FDA grants Fast Track Designation for Emergent BioSolutions' NuThrax vaccine

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.